Welcome to our dedicated page for NOVONIX SEC filings (Ticker: NVNXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NOVONIX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NOVONIX's regulatory disclosures and financial reporting.
NOVONIX Limited reports a leadership transition in its finance team. Chief Financial Officer Robert Long will leave the company in July to pursue other opportunities. Current Chair Ron Edmonds, a veteran finance leader formerly with Dow Chemical, will serve as Interim Chief Financial Officer and step aside as Chair during the search for a permanent replacement. Deputy Chair Admiral Robert Natter will take over as Chair so Edmonds can focus on the interim CFO role. The Board states it is confident these arrangements will maintain leadership continuity and support ongoing operations while a new full-time CFO is recruited.
NOVONIX Ltd Chief Operating Officer Dwayne Arnold Johnson reported six Form 4 transactions involving performance rights linked to ordinary shares. All are coded as “other acquisition or disposition” (code J) and classified as restructuring transactions covering an aggregate 2,932,881 performance rights at an exercise price of $0.0000 per right. No shares were reported as bought or sold, and the transaction summary shows zero net buy or sell activity.
NOVONIX Ltd director Robert J. Natter reported internal transfers of company shares between accounts he beneficially owns. On the reported date, three “J” code transactions moved a total of 460,686 ordinary shares among direct holdings and family trusts at a stated price of $0.0000 per share.
A footnote explains these were administrative transfers and did not change his overall economic interest in NOVONIX securities. He also holds share rights over 195,938 underlying ordinary shares with a stated exercise price of $0.0000 and an expiration date of December 31, 2027.
NOVONIX Ltd director Tony Bellas reported his derivative holdings of share rights linked to ordinary shares. The filing shows 195,938 underlying ordinary shares tied to these share rights at an exercise price of $0.0000 per share, exercisable from December 31, 2026 and expiring on December 31, 2027. No purchases or sales were reported; this entry updates his position in these rights.
NOVONIX Ltd director Jean Oelwang reported a derivative holding of 195,938 share rights linked to ordinary shares. These share rights have an exercise price of $0.0000 and are scheduled to expire on December 31, 2027. The filing shows 195,938 underlying ordinary shares associated with this position, with no buy or sell transactions indicated in the provided data.
NOVONIX Ltd director Ronald C. Edmonds reported his holdings of share rights linked to the company’s ordinary shares. The filing shows share rights over 195,938 underlying ordinary shares with an exercise price of $0.00 per share, exercisable from December 31, 2026 and expiring on December 31, 2027. This entry reflects a reported position rather than a new purchase or sale.
NOVONIX Ltd director Burrow Sharan reported a holding of 195,938 share rights linked to ordinary shares. These rights have a zero exercise price and are scheduled to become exercisable on December 31, 2026, with an expiration date of December 31, 2027. The filing reflects a position update rather than a new buy or sell transaction.
NOVONIX Ltd director and Chief Executive Officer Michael O'Kronley reported his existing derivative holdings in the form of performance rights. These rights relate to 5,862,567 underlying ordinary shares, have an exercise price of $0.0000, become exercisable on December 31, 2028, and expire on December 31, 2029. The entry is recorded as a holding, with no buy or sell transaction reported.
Novonix Limited filed a Form 6-K that includes an ASX Appendix 3Y detailing a change in director interests for Michael O’Kronley. The filing records the issue of performance rights to the director following shareholder approval at the AGM held on 15 April 2026.
After this change, Michael O’Kronley holds 9,586,538 performance rights. The notice also confirms that the interests were not traded during a closed period, so no special trading clearance was required.
NOVONIX Limited reports key strategic and cash developments for the quarter ended 31 March 2026. The U.S. Government certified the company’s Riverside project for a previously allocated US$103 million Section 48C advanced manufacturing tax credit, expected when the first 11,000 tonnes per annum of capacity is placed in service before 7 April 2028, with credits that can be sold to a third party.
NOVONIX signed a binding term sheet to divest its Battery Technology Solutions business while retaining a 15% equity stake, and secured exclusive rights to evaluate buying adjacent Riverside land for US$26.5 million, a move the company says could enable more than US$200 million in potential capital savings if a 50,000 tpa build-out is consolidated on one site. The company also highlighted revised mass production timing for Panasonic Energy to the second half of 2027 and a changing U.S. trade environment for anode materials.
Financially, NOVONIX posted a quarterly operating cash outflow of US$14.4 million and invested US$6.8 million in property, plant, and equipment, mainly at Riverside. Cash and cash equivalents were US$57.1 million at quarter-end, equating to an estimated 4.0 quarters of funding based on recent cash usage. The company also received notice from Nasdaq that its ADRs no longer meet the US$1.00 minimum bid price requirement and is assessing options such as adjusting the ADR-to-ordinary share ratio.